Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: A randomised controlled trial [ISRCTN88246634]

BMC Gastroenterology

Volumn 4, Issue , 2004, Pages

  ter Borg, Pieter C J ^a   van Os, Erik ^a   van den Broek, Walter W ^a   Hansen, Bettina E ^a   van Buuren, Henk R ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FLUVOXAMINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; INTRAHEPATIC CHOLESTASIS; MALE; NAUSEA; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT WITHDRAWAL; VISUAL ANALOG SCALE; BILIARY CIRRHOSIS; CHEMICALLY INDUCED DISORDER; DIZZINESS; MIDDLE AGED; SCLEROSING CHOLANGITIS; TREATMENT OUTCOME;

CHOLANGITIS, SCLEROSING; DIZZINESS; FATIGUE; FEMALE; FLUVOXAMINE; HEADACHE; HUMANS; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; NAUSEA; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 10444261805     PISSN: 1471230X     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-4-13     Document Type: Article

References (15)

1. van Hoogstraten HJF, Hansen BE, van Buuren HR, ten Kate FJW, van Berge Henegouwen GP, Schalm SW: Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. J Hepatol 1999, 31: 56-262.
2. Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, Prytz H, Sandberg-Gertzen H, Wallerstedt S, Lindberg G: Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996, 38:610-615.
3. Huet PM, Deslauriers J, Tran A, Faucher C, Charbonneau J: Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. Am J Gastroenterol 2000, 95:760-767.
4. Wiesner RH, LaRusso NF, Ludwig J, Dickson ER: Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis. Gastroenterology 1985, 88: 08-114.
5. Gluud C, Christensen E: Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2002:CD000551.
6. van Hoogstraten HJF, Wolfhagen FHJ, van de Meeberg PC, Kuiper H, Nix GAJJ, Becx MCJM, Hoek AC, van Houte DPF, Rijk MCM, Salemans JMJI, Scherpenisse J, Schrijver M, Smit AM, Spoelstra P, Stadhouders PHGM, Tan TG, Hop WCJ, ten Kate FJW, van Berge Henegouwen GP, Schalm SW, van Buuren HR: Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J Hepatol 1998, 29:417-423.
7. Beck AT, Ward CH, Mendelson M: An inventory for measuring depression. Arch Gen Psychiatry 1961, 6:561-571.
8. Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF: Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994, 18 Suppl 1: 79-83.
9. Smets EM, Visser MR, Willems-Groot AF, Garssen B, Oldenburger F, van Tienhoven G, de Haes JC: Fatigue and radiotherapy: (A) experience in patients undergoing treatment. Br J Cancer 1998, 78:899-906.
10. Prince MI, James OF, Holland NP, Jones DE: Validation of a fatigue impact score in primary biliary cirrhosis: towards a standard for clinical and trial use. J Hepatol 2000, 32:368-373.
11. Ware J. E., Jr., Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483.
12. Cauch-Dudek K, Abbey S, Stewart DE, Heathcote EJ: Fatigue in primary biliary cirrhosis. Gut 1998, 43:705-710.
13. O'Malley PG, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL: Treatment of fibromyalgia with antidepressants: a metaanalysis. J Gen Intern Med 2000, 15:659-666.
14. Vercoulen JH, Swanink CM, Zitman FG, Vreden SG, Hoofs MP, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G: Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet 1996, 347:858-861.
15. Wearden AJ, Morriss RK, Mullis R, Strickland PL, Pearson DJ, Appleby L, Campbell IT, Morris JA: Randomised, double-blind, placebo-controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome. Br J Psychiatry 1998, 172: 85-490.